"TASQ"@en . . . . . . . . . "investigational"@en . . "Investigated for use/treatment in prostate cancer."@en . . . . . . "tasquinimod"@en . . . "# Dalrymple SL, Becker RE, Isaacs JT: The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts. Prostate. 2007 May 15;67(7):790-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17373719 # Isaacs JT, Pili R, Qian DZ, Dalrymple SL, Garrison JB, Kyprianou N, Bjork A, Olsson A, Leanderson T: Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate. 2006 Dec 1;66(16):1768-78. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16955399"@en . . . . "The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts"@en . . . . . . . . . . . . .